Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease

NIH Image to ImageJ: 25 years of image analysis

Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · see citing works

Simultaneous Inference in General Parametric Models

Hothorn, T., Bretz, F., & Westfall, P. H. (2008) · Biometrical Journal · doi:10.1002/bimj.200810425 · Cited by 13,950 · see citing works

The control of the false discovery rate in multiple testing under dependency

Benjamini, Y., & Yekutieli, D. (2001) · The Annals of Statistics · doi:10.1214/aos/1013699998 · Cited by 10,490 · see citing works

Arzneimittelforschung

Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,401 · see citing works

Generalized Linear Models

Nelder, J. A., & Wedderburn, R. W. M. (1972) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2344614 · Cited by 7,321 · see citing works

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works

Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · see citing works

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works

Untitled work

Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · see citing works

2018 Alzheimer's disease facts and figures

Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912 · see citing works

Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 745 · see citing works

β-Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease

Fukumoto, H. (2002) · Archives of Neurology · doi:10.1001/archneur.59.9.1381 · Cited by 694 · see citing works

Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease

Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562 · see citing works

An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript

Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551 · see citing works

Rivastigmine for Alzheimer’s disease.

Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534 · see citing works

Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier

Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477 · see citing works

Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway

Murakami, S., Kan, M., McKeehan, W. L., & Crombrugghe, B. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1113 · Cited by 377 · see citing works

Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein.

Jaffe, A. B., Toran‐Allerand, C. D., Greengard, P., & Gandy, S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36796-0 · Cited by 363 · see citing works

Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice

Méziane, H., Dodart, J., Mathis, C., Little, S. H., Clemens, J. A., Paul, S. M., & Ungerer, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12683 · Cited by 355 · see citing works

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

Feldman, H., Ferris, S. H., Winblad, B. G., Sfikas, N., Mancione, L., He, Y., Tekin, S., Burns, A. S., Cummings, J. L., del Ser, T., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70109-6 · Cited by 335 · see citing works

GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1314 · Cited by 319 · see citing works

β-Secretase Activity Increases with Aging in Human, Monkey, and Mouse Brain

Fukumoto, H., Rosene, D. L., Moss, M. B., Raju, S., Hyman, B. T., & Irizarry, M. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63159-8 · Cited by 294 · see citing works

Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels <i>in vivo</i>

Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., & Thiele, D. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031520100 · Cited by 294 · see citing works

Translation of the Alzheimer Amyloid Precursor Protein mRNA Is Up-regulated by Interleukin-1 through 5′-Untranslated Region Sequences

Rogers, J. T., Leiter, L. M., McPhee, J., Cahill, C. M., Zhan, S.-S., Potter, H., & Nilsson, L. N. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6421 · Cited by 290 · see citing works

Rivastigmine for Alzheimer's disease

Birks, J., & Evans, J. G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub3 · Cited by 247 · see citing works

Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activity

Kim, M., Suh, J., Romano, D., Truong, M. H., Mullin, K., Hooli, B., Norton, D., Tesco, G., Elliott, K., Wagner, S. L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp323 · Cited by 234 · see citing works

Stop Alzheimer’s before it starts

McDade, E., & Bateman, R. J. (2017) · Nature · doi:10.1038/547153a · Cited by 228 · see citing works

ADAM10 Missense Mutations Potentiate β-Amyloid Accumulation by Impairing Prodomain Chaperone Function

Suh, J., Choi, S. H., Romano, D. M., Gannon, M. A., Lesinski, A. N., Kim, D. Y., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.08.035 · Cited by 217 · see citing works

MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed

Long, J. M., & Lahiri, D. K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.053 · Cited by 209 · see citing works

Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development

Shaw, K. T. Y., Utsuki, T., Rogers, J. T., Yu, Q., Sambamurti, K., Brossi, A. R., Ge, Y., Lahiri, D. K., & Greig, N. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131152998 · Cited by 206 · see citing works

MicroRNA-153 Physiologically Inhibits Expression of Amyloid-β Precursor Protein in Cultured Human Fetal Brain Cells and Is Dysregulated in a Subset of Alzheimer Disease Patients

Long, J. M., Ray, B., & Lahiri, D. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366336 · Cited by 198 · see citing works

Protective Role of Ashwagandha Leaf Extract and Its Component Withanone on Scopolamine-Induced Changes in the Brain and Brain-Derived Cells

Konar, A., Shah, N., Singh, R., Saxena, N., Kaul, S. C., Wadhwa, R., & Thakur, M. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027265 · Cited by 193 · see citing works

Selective Translational Control of the Alzheimer Amyloid Precursor Protein Transcript by Iron Regulatory Protein-1

Cho, H.-H., Cahill, C. M., Vanderburg, C. R., Scherzer, C. R., Wang, B., Huang, X., & Rogers, J. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149161 · Cited by 188 · see citing works

MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects

Long, J. M., Ray, B., & Lahiri, D. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518241 · Cited by 187 · see citing works

Acute function of secreted amyloid precursor protein fragment APPsα in synaptic plasticity

Hick, M., Herrmann, U., Weyer, S. W., Mallm, J., Tschäpe, J., Borgers, M., Mercken, M. H., Roth, F. C., Draguhn, A., Slomianka, L., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1368-x · Cited by 186 · see citing works

Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease

Sambamurti, K., Greig, N. H., & Lahiri, D. K. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:1:1:1 · Cited by 184 · see citing works

University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology

Schmitt, F. A., Nelson, P. T., Abner, E. L., Scheff, S. W., Jicha, G. A., Smith, C. D., Cooper, G. E., Mendiondo, M. S., Danner, D. D., Eldik, L. J. V., et al. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322591 · Cited by 184 · see citing works

Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model

Fol, R. R., Braudeau, J., Ludewig, S., Abel, T., Weyer, S. W., Roederer, J.-P., Brod, F., Audrain, M., Bemelmans, A., Buchholz, C. J., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1498-9 · Cited by 168 · see citing works

Evaluation of the Contribution of Different ADAMs to Tumor Necrosis Factor α (TNFα) Shedding and of the Function of the TNFα Ectodomain in Ensuring Selective Stimulated Shedding by the TNFα Convertase (TACE/ADAM17)

Zheng, Y., Säftig, P., Hartmann, D., & Blobel, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403193200 · Cited by 158 · see citing works

Epigenetics of dementia: understanding the disease as a transformation rather than a state

Maloney, B., & Lahiri, D. K. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00065-x · Cited by 154 · see citing works

Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice

Furukawa‐Hibi, Y., Alkam, T., Nitta, A., Matsuyama, A., Mizoguchi, H., Suzuki, K., Moussaoui, S. M., Yu, Q.-S., Greig, N. H., Nagai, T., et al. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.035 · Cited by 150 · see citing works

From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.

Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150 · see citing works

Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease

Rogers, J. T., Bush, A. I., Cho, H.-H., Smith, D. H., Thomson, A. M., Friedlich, A. L., Lahiri, D. K., Leedman, P. J., Huang, X., & Cahill, C. M. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361282 · Cited by 148 · see citing works

Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5′-untranslated region: Implications in Alzheimer’s disease

Long, J. M., Maloney, B., Rogers, J. T., & Lahiri, D. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0266-3 · Cited by 141 · see citing works

Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease

Fisher, A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07507.x · Cited by 140 · see citing works

Deletion of M ₁ Muscarinic Acetylcholine Receptors Increases Amyloid Pathology <i>In Vitro</i> and <i>In Vivo</i>

Davis, A. A., Fritz, J. J., Wess, J., Lah, J. J., & Levey, A. I. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.6393-09.2010 · Cited by 137 · see citing works

The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice

Lahiri, D. K., Chen, D., Maloney, B., Holloway, H. W., Yu, Q.-S., Utsuki, T., Giordano, T., Sambamurti, K., & Greig, N. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112102 · Cited by 134 · see citing works

Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients

Olsson, A., Höglund, K., Sjögren, M. J. C., Andreasen, N., Minthon, L., Lannfelt, L., Büerger, K., Möller, H., Hampel, H. J., Davidsson, P., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00027-x · Cited by 132 · see citing works

Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

Dam, D. V., Abramowski, D., Staufenbiel, M., & Deyn, P. P. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2132-z · Cited by 130 · see citing works

An EGFR-ERK-SOX9 Signaling Cascade Links Urothelial Development and Regeneration to Cancer

Ling, S., Chang, X., Schultz, L., Lee, T. K. M., Chaux, A., Marchionni, L., Netto, G. J., Sidransky, D., & Berman, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3072 · Cited by 121 · see citing works

ADAM-10 over-expression increases cortical synaptogenesis

Bell, K. F. S., Zheng, L., Fahrenholz, F., & Cuello, A. C. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.004 · Cited by 120 · see citing works

Increased Secreted Amyloid Precursor Protein-α (sAPPα) in Severe Autism: Proposal of a Specific, Anabolic Pathway and Putative Biomarker

Ray, B., Long, J. M., Sokol, D. K., & Lahiri, D. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020405 · Cited by 119 · see citing works

Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα

Mockett, B. G., Richter, M., Abraham, W. C., & Müller, U. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00030 · Cited by 115 · see citing works

Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 114 · see citing works

A Closer Look at α-Secretase

Postina, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954668 · Cited by 110 · see citing works

The Neuroprotective Properties of the Amyloid Precursor Protein Following Traumatic Brain Injury

Plummer, S. L., van den Heuvel, C., Thornton, E., Corrigan, F., & Cappai, R. (2016) · Aging and Disease · doi:10.14336/ad.2015.0907 · Cited by 103 · see citing works

MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties

Chopra, N., Wang, R., Maloney, B., Nho, K. T., Beck, J. S., Pourshafie, N., Niculescu, A. B., Saykin, A. J., Rinaldi, C., Counts, S., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0610-2 · Cited by 101 · see citing works

Part-Time &amp;#945;-Secretases: The Functional Biology of ADAM 9, 10 and 17

Deuss, M., Reiss, K., & Hartmann, D. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954686 · Cited by 98 · see citing works

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

Maccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 96 · see citing works

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease

Ismail, M. F., ElMeshad, A. N., & Salem, N. A. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s39232 · Cited by 94 · see citing works

The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site

Wong, E., Maretzky, T., Peleg, Y., Blobel, C., & Sagi, I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624072 · Cited by 92 · see citing works

APP as a Protective Factor in Acute Neuronal Insults

Hefter, D., & Draguhn, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00022 · Cited by 89 · see citing works

Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein

Bodovitz, S., Falduto, M. T., Frail, D. E., & Klein, W. L. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010307.x · Cited by 86 · see citing works

Treatment for Alzheimer’s disease: has anything changed?

Waite, L. M. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.018 · Cited by 85 · see citing works

Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.

Eskander, M. F., Nagykery, N., Leung, E., Khelghati, B., & Geula, C. (2005) · Brain Research · doi:10.1016/j.brainres.2005.08.039 · Cited by 84 · see citing works

Targeting the Prodromal Stage of Alzheimer's Disease: Bioenergetic and Mitochondrial Opportunities

Caldwell, C. C., Yao, J., & Brinton, R. D. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0324-8 · Cited by 83 · see citing works

EGCG functions through estrogen receptor‐mediated activation of ADAM10 in the promotion of non‐amyloidogenic processing of APP

Fernandez, J. W., Rezai-Zadeh, K. P., Obregon, D. F., & Tan, J. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.09.022 · Cited by 83 · see citing works

Cerebrospinal Fluid Levels of -Secretase--Cleaved Soluble Amyloid Precursor Protein Mirror Cognition in a Swedish Family With Alzheimer Disease and a Gene Mutation

Almkvist, O., Basun, H., Wagner, S. L., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550170111022 · Cited by 80 · see citing works

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: A Bayesian network meta-analysis

Kobayashi, H., Ohnishi, T., Nakagawa, R., & Yoshizawa, K. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4405 · Cited by 79 · see citing works

Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid‐differentiated human neuroblastoma cells

Holback, S., Adlerz, L., & Iverfeldt, K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03440.x · Cited by 72 · see citing works

Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease

Rosén, C., Andréasson, U., Mattsson, N., Marcusson, J. O., Minthon, L., Andreasen, N., Blennow, K., & Zetterberg, H. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8171-4 · Cited by 72 · see citing works

Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives

Sun, Y., Yang, F., Lin, C., & Han, Y. (2015) · CNS Neuroscience &amp; Therapeutics · doi:10.1111/cns.12395 · Cited by 71 · see citing works

Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons

Bailey, J. A., Ray, B., Greig, N. H., & Lahiri, D. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021954 · Cited by 70 · see citing works

Does Intraneuronal Accumulation of Carboxyl-terminal Fragments of the Amyloid Precursor Protein Trigger Early Neurotoxicity in Alzheimer’s Disease?

Lauritzen, I., Pardossi‐Piquard, R., Bourgeois, A., Bécot, A., & Checler, F. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190325092841 · Cited by 67 · see citing works

Role of ADAM-9 Disintegrin-Cysteine-rich Domains in Human Keratinocyte Migration

Zigrino, P., Steiger, J., Fox, J. W., Löffek, S., Schild, A., Nischt, R., & Mauch, C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701658200 · Cited by 66 · see citing works

Differential Accumulation of Secreted AβPP Metabolites in Ocular Fluids1

Prakasam, A., Muthuswamy, A., Ablonczy, Z., Greig, N. H., Fauq, A. H., Rao, K. S. J., Pappolla, M. A., & Sambamurti, K. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100210 · Cited by 65 · see citing works

Interleukin‐1α stimulates non‐amyloidogenic pathway by α‐secretase (ADAM‐10 and ADAM‐17) cleavage of APP in human astrocytic cells involving p38 MAP kinase

Bandyopadhyay, S., Hartley, D. M., Cahill, C. M., Lahiri, D. K., Chattopadhyay, N., & Rogers, J. T. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20864 · Cited by 65 · see citing works

Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats

Wang, R. H., Bejar, C., & Weinstock, M. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00157-4 · Cited by 63 · see citing works

Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model

Mohamed, L. A., Keller, J. N., & Kaddoumi, A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.01.013 · Cited by 63 · see citing works

Reduced cerebrospinal fluid levels of α-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits

Anderson, J. J., Höltz, G., Baskin, P. P., Wang, R., Mazzarelli, L., Wagner, S. L., & Menzaghi, F. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00244-4 · Cited by 62 · see citing works

Huperzine a alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice

Wang, Y., Tang, X. C., & Zhang, H. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22775 · Cited by 60 · see citing works

Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease

Scacchi, R., Gambina, G., Broggio, E., & Corbo, R. M. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4043 · Cited by 58 · see citing works

Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats

Mohamed, L. A., Qosa, H., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00040 · Cited by 58 · see citing works

Cognitive complaints in older adults at risk for Alzheimer's disease are associated with altered resting‐state networks

Contreras, J. A., Goñi, J., Risacher, S. L., Amico, E., Yoder, K. K., Džemidžić, M., West, J. D., McDonald, B. C., Farlow, M. R., Sporns, O., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.004 · Cited by 57 · see citing works

Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment

Ferris, S. H., Nordberg, A. K., Soininen, H. S., Darreh‐Shori, T., & Lane, R. M. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832f8c17 · Cited by 55 · see citing works

Effects of TNFα-Converting Enzyme Inhibition on Amyloid β Production and APP ProcessingIn VitroandIn Vivo

Kim, M. L., Zhang, B., Mills, I. P., Milla, M. E., Brunden, K. R., & Lee, V. M. ‐. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2913-08.2008 · Cited by 53 · see citing works

Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer’s disease

Perneczky, R., Guo, L.-H., Kagerbauer, S. M., Werle, L., Kurz, A., Martin, J., & Alexopoulos, P. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.11 · Cited by 53 · see citing works

A novel effect of rivastigmine on pre‐synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease

Bailey, J. A., & Lahiri, D. K. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06490.x · Cited by 53 · see citing works

M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera

Konar, A., Gupta, R., Shukla, R. K., Maloney, B., Khanna, V. K., Wadhwa, R., Lahiri, D. K., & Thakur, M. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-48238-6 · Cited by 53 · see citing works

Do Cholinesterase Inhibitors Act Primarily on Attention Deficit? A Naturalistic Study in Alzheimer's Disease Patients

Bracco, L., Bessi, V., Padiglioni, S., Marini, S., & Pepeu, G. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131154 · Cited by 51 · see citing works

Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: Change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau

Ray, B., Reyes, P. F., & Lahiri, D. K. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.011 · Cited by 51 · see citing works

The amyloid precursor protein and its homologues: Structural and functional aspects of native and pathogenic oligomerization

Kaden, D., Munter, L. M., Reif, B., et al. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.01.017 · Cited by 51 · see citing works

Soluble β-amyloid Precursor Protein Alpha Binds to p75 Neurotrophin Receptor to Promote Neurite Outgrowth

Hasebe, N., Fujita, Y., Ueno, M., Yoshimura, K., Fujino, Y., & Yamashita, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082321 · Cited by 50 · see citing works

Rivastigmine improves hippocampal neurogenesis and depression-like behaviors via 5-HT1A receptor stimulation in olfactory bulbectomized mice

Islam, M. R., Moriguchi, S., Tagashira, H., & Fukunaga, K. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.046 · Cited by 49 · see citing works

Rivastigmine Alleviates Experimentally Induced Colitis in Mice and Rats by Acting at Central and Peripheral Sites to Modulate Immune Responses

Shifrin, H., Nadler-Milbauer, M., Shoham, S., & Weinstock, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057668 · Cited by 49 · see citing works

Human primary mixed brain cultures: preparation, differentiation, characterization and application to neuroscience research

Ray, B., Chopra, N., Long, J. M., & Lahiri, D. K. (2014) · Molecular Brain · doi:10.1186/s13041-014-0063-0 · Cited by 47 · see citing works

Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cells

Ray, B., Banerjee, P., Greig, N. H., & Lahiri, D. K. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.016 · Cited by 45 · see citing works

Characterization of the APP proximal promoter and 5′‐untranslated regions: identification of cell‐type specific domains and implications in APP gene expression and Alzheimer's disease

Lahiri, D. K., Ge, Y., & Maloney, B. (2005) · The FASEB Journal · doi:10.1096/fj.04-2900fje · Cited by 43 · see citing works

Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice

Siopi, E., Llufriu-Dabén, G., Cho, A. H., Vidal-Lletjós, S., Plotkine, M., Marchand‐Leroux, C., & Jafarian-Tehrani, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.009 · Cited by 43 · see citing works

Amyloid Precursor Protein Compartmentalization Restricts β-Amyloid Production: Therapeutic Targets Based on BACE Compartmentalization

Gandhi, S., Refolo, L. M., & Sambamurti, K. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:137 · Cited by 42 · see citing works

Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue

Ray, B., Sokol, D. K., Maloney, B., & Lahiri, D. K. (2016) · Scientific Reports · doi:10.1038/srep26052 · Cited by 42 · see citing works

Differential effect of tacrine and physostigmine on the secretion of the β-amyloid precursor protein in cell lines

Lahiri, D. K., & Farlow, M. R. (1996) · Journal of Molecular Neuroscience · doi:10.1007/bf02736847 · Cited by 41 · see citing works

Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease

Perneczky, R., Alexopoulos, P., & Initiative, A. D. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.006 · Cited by 41 · see citing works

Amyloid Precursor Protein Protects Neuronal Network Function after Hypoxia via Control of Voltage-Gated Calcium Channels

Hefter, D., Kaiser, M., Weyer, S. W., Papageorgiou, I. E., Both, M., Kann, O., Müller, U., & Draguhn, A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4130-15.2016 · Cited by 41 · see citing works

sAPP Enhances the Transdifferentiation of Adult Bone Marrow Progenitor Cells to Neuronal Phenotypes

Chen, C.-W. D., Boiteau, R. M., Lai, W., Barger, S. W., & Cataldo, A. M. (2006) · Current Alzheimer Research · doi:10.2174/156720506775697205 · Cited by 36 · see citing works

Donepezil modulates amyloid precursor protein endocytosis and reduction by up-regulation of SNX33 expression in primary cortical neurons

Takada‐Takatori, Y., Nakagawa, S., Kimata, R., Nao, Y., Mizukawa, Y., Urushidani, T., Izumi, Y., Akaike, A., Tsuchida, K., & Kume, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-47462-4 · Cited by 35 · see citing works

Soluble Alpha-APP (sAPPalpha) Regulates CDK5 Expression and Activity in Neurons

Hartl, D., Klatt, S., Roch, M., Konthur, Z., Klose, J., Willnow, T. E., & Rohe, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065920 · Cited by 33 · see citing works

Understanding the Beneficial and Detrimental Effects of Donepezil and Rivastigmine to Improve their Therapeutic Value

Lane, R. M., & Darreh‐Shori, T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142268 · Cited by 31 · see citing works

Pharmaceutical Biotechnology

Mazza, P. G. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0 · Cited by 31 · see citing works

ADAM-17 Is Activated by the Mitogenic Protein Kinase ERK in a Model of Kidney Fibrosis

Navar, L. G., Gooz, M. B., Gooz, M., et al. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181cb4487 · Cited by 29 · see citing works

Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine

Wang, R., Schorer-Apelbaum, D., & Weinstock, M. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01498-4 · Cited by 27 · see citing works

Iron dysregulates APP processing accompanying with sAPPα cellular retention and β-secretase inhibition in rat cortical neurons

Chen, Y., Chen, W.-Y., Huang, X., Xu, Y., & Zhang, H. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.113 · Cited by 27 · see citing works

Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach

Ferris, S. H., Lane, R. M., Sfikas, N., et al. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.06.004 · Cited by 24 · see citing works

Efficient DNA transfection in neuronal and astrocytic cell lines

Ghosh, C., Song, W., & Lahiri, D. K. (2000) · Molecular Biology Reports · doi:10.1023/a:1007173906990 · Cited by 22 · see citing works

High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies.

Amini, H., & Ahmadiani, A. (2010) · Europe PMC (PubMed Central) · Cited by 18 · see citing works

Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo : A Microdialysis Study

Welt, T., Kulic, L., Hoey, S. E., McAfoose, J., Späni, C. B., Chadha, A. S., Fisher, A., & Nitsch, R. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150152 · Cited by 18 · see citing works

Sox9-dependent transcriptional regulation of the proprotein convertase furin

Guimont, P., Grondin, F., & Dubois, C. M. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00349.2006 · Cited by 15 · see citing works

Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease

Lahiri, D. K., Alley, G. M., Tweedie, D., et al. (2007) · NeuroMolecular Medicine · doi:10.1007/bf02685889 · Cited by 13 · see citing works

Gender Differences in the Pharmacokinetics of Rivastigmine in Rats

Arumugam, K., Chamallamudi, M., Mallayasamy, S., Ganesan, S., Shavi, G. V., Ranjithkumar, A., Ravindranath Reddy, D. R., Bhat, K., & Udupa, N. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296432 · Cited by 8 · see citing works

Role of Cholinergic Signaling in Alzheimer’s Disease

Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F. (2022) · Molecules · doi:10.3390/molecules27061816 · Cited by 922 · see citing works

Selective Secretase Targeting for Alzheimer’s Disease Therapy

Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66 · see citing works

Phycocyanin alleviates ICV-STZ induced cognitive and molecular deficits via PI3-Kinase dependent pathway

Agrawal, M., Perumal, Y., Bansal, S., Arora, S., & Chopra, K. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111684 · Cited by 54 · see citing works

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works

Molecular mechanisms of Alzheimer’s disease: From therapeutic targets to promising drugs

Alan, E., Kerry, Z., & Sevin, G. (2023) · Fundamental &amp; Clinical Pharmacology · doi:10.1111/fcp.12861 · Cited by 17 · see citing works

Patient Adherence to Transdermal Rivastigmine After Switching From Oral Donepezil

Tian, H., Abouzaid, S., Chen, W., Kahler, K. H., & Kim, E. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318266fb02 · Cited by 19 · see citing works

PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE

Sicras, A., Vergara, J., León, T., et al. (2005) · Value in Health · doi:10.1016/s1098-3015(10)67542-0 · Cited by 10 · see citing works

EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTSWITH ALZHEIMER'S DISEASE

Alfazli, R. A., Shahi, S., & Nazeman, M. (2008) · ACTA MEDICA IRANICA

Donepezil, Rivastigmine and Galantamine: Cholinesterase Inhibitors for Alzheimer's Disease

Sakya, S. M., & Karki, K. (2010) · doi:10.1002/9780470768594.ch17 · Cited by 3 · see citing works

PNL5 DRUG PERSISTENCY OF TWO CHOLINESTERASE INHIBITORS—RIVASTIGMINE VERSUS DONEPEZIL AMONG ELDERLY PATIENTS WITH ALZHEIMER'S DISEASE

Suh, D., Thomas, S., Valiyeva, E., et al. (2005) · Value in Health · doi:10.1016/s1098-3015(10)62819-7